TLSA Tiziana Life Sciences plc

5.73
+0.58  (+11%)
Previous Close 5.15
Open 5.75
Price To Book -52.09
Market Cap 184,238,844
Shares 32,153,376
Volume 366,391
Short Ratio
Av. Daily Volume 485,948
Stock charts supplied by TradingView

NewsSee all news

  1. Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company

    NEW YORK and LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, AIM: TILS)), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and

  2. Tiziana Lifesciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, AIM: TILS))

  3. Tiziana Life Sciences Announces Data Demonstrating StemPrintER's Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the

  4. Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference

    NEW YORK and LONDON, May 11, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune

  5. Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a data noted 4% partial response rate; 61% stable disease - September 3, 2019.
Milciclib
Hepatocellular carcinoma (HCC)
Phase 2b trial to be initiated 2H 2019.
Milciclib and Sorafenib (Nexavar)
Hepatocellular carcinoma (HCC)
Phase 1 completion announced January 9, 2020.
Foralumab
Healthy human volunteers
Phase 1 trial planned.
TZLS-501
Coronavirus COVID-19

Latest News

  1. Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company

    NEW YORK and LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, AIM: TILS)), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and

  2. Tiziana Lifesciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, AIM: TILS))

  3. Tiziana Life Sciences Announces Data Demonstrating StemPrintER's Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the

  4. Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference

    NEW YORK and LONDON, May 11, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune

  5. Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the

  6. Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia

    Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood This announcement contains inside information for the purposes of Article 7 of EU

  7. Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies

    NEW YORK and LONDON, April 09, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune

  8. Tiziana Announces Closing of Offering and Resulting Total Voting Rights

    LONDON and NEW YORK, March 16, 2020 /PRNewswire/ -- Tiziana Life Sciences plc (NASDAQ:TLSA) (AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery

  9. Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 Million

    NEW YORK and LONDON, March 11, 2020 /PRNewswire/ -- Tiziana Life Sciences plc (NASDAQ:TLSA) (AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery

  10. Tiziana Life Sciences Developing TZLS-501 as a Potential Treatment for Coronavirus Patients

    LONDON, March 11, 2020 /PRNewswire/ -- Nasdaq and AIM listed Tiziana Life Sciences plc (NASDAQ:TLSA) (AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with

  11. Tiziana Life Sciences Announces Appointment of Mr. Gregor MacRae to strengthen the Board

    Tiziana Life Sciences plc ("Tiziana" or the "Company") (NASDAQ:TLSA), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology

  12. Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative

  13. Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers

    A breakthrough approach for treatment of autoimmune and inflammatory diseases THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET

  14. Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers

    THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A

  15. Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma

    Tiziana Life Sciences plc (NASDAQ:TLSA), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase

  16. Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma

    Tiziana Life Sciences plc (NASDAQ:TLSA), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase

  17. Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma

    Tiziana Life Sciences plc (NASDAQ:TLSA), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase